The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Alasdair P. MacGowan

Bristol Centre for Antimicrobial Research and Evaluation

Southmead Health Services NHS Trust and University of Bristol

Bristol

United Kingdom

[email]@*.swest.nhs.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Bristol, United Kingdom. 1999 - 2003
  • Department of Medical Microbiology, Bristol Centre for Antimicrobial Research and Evaluation, University of Bristol and North Bristol NHS Trust, Southmead Hospital, UK. 2002
  • Department of Medical Microbiology, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, UK. 2001

References

  1. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. MacGowan, A.P., Rogers, C.A., Holt, H.A., Bowker, K.E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  2. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. MacGowan, A.P., Bowker, K.E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  3. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. MacGowan, A., Bowker, K. Int. J. Antimicrob. Agents (2002) [Pubmed]
  4. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. MacGowan, A.P., Wise, R. J. Antimicrob. Chemother. (2001) [Pubmed]
  5. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?. MacGowan, A., Rogers, C., Bowker, K. Clin. Infect. Dis. (2001) [Pubmed]
  6. Role of pharmacokinetics and pharmacodynamics: does the dose matter?. MacGowan, A.P. Clin. Infect. Dis. (2001) [Pubmed]
  7. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. MacGowan, A.P., Rogers, C.A., Holt, H.A., Wootton, M., Bowker, K.E. Antimicrob. Agents Chemother. (2001) [Pubmed]
  8. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. MacGowan, A., Rogers, C., Holt, H.A., Wootton, M., Bowker, K. J. Antimicrob. Chemother. (2000) [Pubmed]
  9. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. MacGowan, A., Rogers, C., Bowker, K. J. Antimicrob. Chemother. (2000) [Pubmed]
  10. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. MacGowan, A.P., Bowker, K.E., Wootton, M., Holt, H.A. Antimicrob. Agents Chemother. (1999) [Pubmed]
 
WikiGenes - Universities